Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA7 | P43166 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.53 |
| ▸ | XDH | P47989 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30010685 | 1.00 | TDP1 (0.53) | TDP1CA1CA2CA12CA7 | |
| SCHEMBL1459771 | 0.85 | TDP1 (0.53) | TDP1CA1CA2CA12CA7 | |
| SCHEMBL550572 | 0.84 | CA1 (0.57) | TDP1CA1CA2CA12CA7 | |
| SCHEMBL204112 | 0.82 | CA1 (0.55) | TDP1CA1CA2CA12CA7 | |
| SCHEMBL17656285 | 0.82 | HCRTR1 (0.48) | TDP1CA1CA2CA12CA7 | |
| SCHEMBL35783 | 0.82 | MAPT (0.63) | TDP1CA1CA2CA12CA7 | |
| SCHEMBL30029511 | 0.82 | MAPT (0.63) | TDP1CA1CA2CA12CA7 | |
| SCHEMBL30410030 | 0.81 | CA12 (0.59) | CA1CA2CA12CA7CA9 | |
| SCHEMBL2228061 | 0.81 | CA12 (0.59) | CA1CA2CA12CA7CA9 | |
| SCHEMBL490266 | 0.81 | KDM4E (0.62) | TDP1CA1CA2CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 296 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119462376-A | Synthesis process of panatinib key intermediate | 湖北广济医药科技有限公司 | 2025-02-18 | — | — | CN | claimed |
| CN-116284074-A | Synthesis process of 5-carboxylic acid-2-methylphenylboronic acid | 上海泰坦科技股份有限公司 | 2023-06-23 | — | — | CN | claimed |
| CN-103664951-B | A kind of preparation method treating chronic myelocytic leukemia medicine | 南京圣和药业股份有限公司 | 2016-10-05 | — | — | CN | claimed |
| CN-103664951-A | Preparation method of drug for treating chronic granulocytic leukemia | NANJING SANHOME PHARMACEUTICAL CO LTD | 2014-03-26 | — | — | CN | claimed |
| CN-120842220-B | Aryl amide compound and application thereof | 暨南大学 | 2026-05-19 | — | — | CN | disclosed |
| EP-4739682-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| US-12509424-B2 | Compound and composition as PDGF receptor kinase inhibitor | NIPPON SHINYAKU CO., LTD. (JP) | 2025-12-30 | — | — | US | disclosed |
| US-12440494-B2 | Compounds useful for inhibiting RAF dimers | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250304535-A1 | KAT6 Inhibitors | BEIGENE SWITZERLAND GMBH (CH) | 2025-10-02 | — | — | US | disclosed |
| WO-2025201504-A1 | KAT6 INHIBITORS | BEIGENE (SUZHOU) CO., LTD. (CN) | 2025-10-02 | — | — | WO | disclosed |
| US-12312348-B2 | RET inhibitors, pharmaceutical compositions and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2025-05-27 | — | — | US | disclosed |
| EP-4516777-A2 | COMPOUND AND COMPOSITION AS PDGF RECEPTOR KINASE INHIBITOR | Nippon Shinyaku Co., Ltd. (JP) | 2025-03-05 | — | — | EP | disclosed |
| US-20060199845-A1 | Thiophene compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2006-09-07 | — | — | US | disclosed |
| WO-2006083477-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006083477-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2006-08-10 | — | — | WO | disclosed |
| US-20060173006-A1 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2006-08-03 | — | — | US | disclosed |
| WO-2006081389-A1 | THIOPHENE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2006-08-03 | — | — | WO | disclosed |
| US-20060166990-A1 | Novel aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2006-07-27 | — | — | US | disclosed |
| EP-1658263-A1 | NOVEL AMINOBENZOPHENONE COMPOUNDS | Leo Pharma A/S (DK) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005009940-A1 | NOVEL AMINOBENZOPHENONE COMPOUNDS | LEO PHARMA A/S (DK) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304535-A1 | KAT6 Inhibitors | KAT6A, KAT6B, KAT2A | TDP1 882/4885CA1 1153/4885CA2 3028/4885 |
| US-20060166990-A1 | Novel aminobenzophenone compounds | NFKBIA, UACA, ALDH7A1 | TDP1 2935/4885CA1 4843/4885CA2 3933/4885 |
| US-12509424-B2 | Compound and composition as PDGF receptor kinase inhibitor | PDGFRA, PDGFRB, PDGFA | TDP1 2525/4885CA1 3118/4885CA2 339/4885 |
| US-12440494-B2 | Compounds useful for inhibiting RAF dimers | BRAF, RAF1, NRAS | TDP1 1623/4885CA1 1112/4885CA2 1425/4885 |
| US-12312348-B2 | RET inhibitors, pharmaceutical compositions and uses thereof | RET, SLC10A2, REL | TDP1 1419/4885CA1 1014/4885CA2 449/4885 |
| US-20060199845-A1 | Thiophene compounds for inflammation and immune-related uses | CXCR2, TPMT, CXCR1 | TDP1 1817/4885CA1 1366/4885CA2 407/4885 |
| US-20060173006-A1 | Compounds for inflammation and immune-related uses | CXCL8, CCR8, CXCR2 | TDP1 3644/4885CA1 719/4885CA2 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.